EDIT News and Press, Editas Medicine Inc. From 06/15/23

2023-06-15 04:46:16 ET A clinical-stage genome editing company- Editas Medicine ( NASDAQ: EDIT ) prices 12.5M shares at $10.00 per share. Gross proceeds are expected to be ~$125M. Underwriters have a 30-day option to purchase up to an additional 1.88M shares. The o...

2023-06-14 16:24:29 ET Editas Medicine ( NASDAQ: EDIT ) plans to sell $125 million worth of stock in an underwritten public offering, the company said Wednesday. The underwriters will have a 30-day option to purchase up to an additional $18.8 million in stock. Th...

2023-06-09 10:41:41 ET Editas Medicine ( NASDAQ: EDIT ) on Friday announced initial safety and efficacy data from a pair of trials designed to evaluate EDIT-301, a gene editing candidate targeted at inherited blood disorders, sickle cell disease (SCD), and beta-thalassemia. Citi...

EDIT-301 was well-tolerated and demonstrated a safety profile consistent with myeloablative conditioning with busulfan and autologous hematopoietic stem cell transplant First two RUBY patients achieved normal levels of total hemoglobin and fetal hemoglobin of >40% at 5 months and mai...

CAMBRIDGE, Mass., June 06, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that it will host a live webinar on Monday, June 12, at 8:00 a.m. ET to present clinical data from the RUBY trial of EDIT-301 for the treatm...

2023-05-24 07:24:00 ET Novo Nordisk ( NVO ) has partnered with U.S.-based biotech Life Edit Therapeutics to discover and develop gene editing treatments targeted at rare and cardiometabolic diseases, the companies announced Wednesday. Under the partnership, two companies will focus ...

2023-05-20 08:00:00 ET Summary Beam is a leader in base editing and has strong lab data. It has a huge amount of cash and a major deal with Pfizer. Next year, Beam will produce first human data. I covered Beam Therapeutics (BEAM) in April last year, when the stock ha...

CAMBRIDGE, Mass., May 18, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced the grant of an inducement award to the Company’s newly appointed Chief Financial Officer, Erick Lucera. In connection with Mr. Lucera...

2023-05-16 16:58:22 ET Editas Medicine ( NASDAQ: EDIT ) appoints Erick Lucera as Executive VP and CFO, effective May 17. Lucera replaces Michelle Robertson, who served as CFO since January 2020 and is stepping down. Robertson will remain in an advisory role until August 16...

CAMBRIDGE, Mass., May 16, 2023 (GLOBE NEWSWIRE) --  Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced the appointment of Erick J. Lucera as Executive Vice President and Chief Financial Officer, effective May 17, 2023. Mr. Lucera will succeed Miche...